Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: A critical review of the literature

Inflammation Research

Volumn 53, Issue 10, 2004, Pages 497-508

  Sughrue, M E ^a   Mehra, A ^a   Connolly Jr , E S ^a   D'Ambrosio, A L ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Cerebral ischemia; Clinical trials; Inflammation; Stroke; Therapeutics

Indexed keywords

ANTITHROMBOCYTIC AGENT; CD11B ANTIGEN; CY 1503; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOLYTIC AGENT; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; NERVE CELL ADHESION MOLECULE; NEUROPROTECTIVE AGENT; PADGEM PROTEIN; RECOMBINANT NEUTROPHIL INHIBITORY FACTOR; ROVELIZUMAB; STEROID; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UK 279276; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN;

BRAIN ISCHEMIA; DISEASE COURSE; DRUG TARGETING; FEVER; HUMAN; INFECTION; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STROKE; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; CELL ADHESION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; INFLAMMATION; LEUKOCYTES; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS;

EID: 12144267045     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1282-0     Document Type: Review

References (149)

1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated review. Trends in Neuroscience 1999; 22: 391-7.
2. Gladstone DJ, Black SE, Hakim AM. Heart, Stroke Foundation of Ontario Centre of Excellence in Stroke R. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-36.
3. Fisher M. Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development. Stroke 1999; 30: 2752-8.
4. Fisher M. Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies. Stroke 2001; 32: 1598-606.
5. Fisher M. Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke 2003; 34: 1539-46.
6. Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. [update in Cochrane Database Syst Rev. 2003;(2):CD000029; PMID: 12804384]. Cochrane Database of Systematic Reviews 2000: CD000029.
7. Donnan GA, Hommel M, Davis SM, McNeil JJ. Streptokinase in acute ischaemic stroke. Steering Committees of the ASK and MAST-E trials. Australian Streptokinase Trial. [comment]. Lancet 1995; 346: 56.
8. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. [see comment]. JAMA 1996; 276: 961-6.
9. Anonymous. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. [see comment]. Lancet 1995; 346: 1509-14.
10. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2000: CD000024.
11. Nagahiro S, Uno M, Sato K, Goto S, Morioka M, Ushio Y. Pathophysiology and treatment of cerebral ischemia. Journal of Medical Investigation 1998; 45: 57-70.
12. del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. Thrombosis Research 2000; 98: V73-81.
13. Small DL, Morley P, Buchan AM. Biology of ischemic cerebral cell death. Progress in Cardiovascular Disease 1999; 42: 185-207.
14. Branston NM, Hope DT, Symon L. Barbiturates in focal ischemia of primate cortex: effects on blood flow distribution, evoked potential and extracellular potassium. Stroke 1979; 10: 647-53.
15. Tymianski M, Tator CH. Normal and abnormal calcium homeostasis in neurons: A basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery 1996; 38: 1176-95.
16. Garcia JH, Liu KF, Ye Z, Gutierrez JA. Incomplete infarcts and delayed death after transient middle cerebral artery occlusion in rats. Stroke 1997; 28: 2303-10.
17. Brott T, Bogousslavsky J. Treatment of acute ischemia stroke. New England Journal of Medicine 2000; 343: 710-22.
18. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathology 2000; 10: 95-112.
19. Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion injury after focal cerebral ischemia: The role of inflammation and the therapeutic horizon. Neurosurgery 1998; 43: 1382-97.
20. Dawson D, Ruetzler C, Carlos T, Kochanek P, Hallenbeck J. Polymorphonuclear leukocytes and microcirculatory perfusion in acute stroke in the SHR. Keio J Med 1996; 45: 248-52.
21. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang C. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991; 22: 1276-83.
22. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 1994; 25: 1469-75.
23. Bednar M, Raymond S, McAuliffe T, Lodge P, Gross C. The role of neutrophils and platelets in a rabbit model of thromboembolic stroke. Stroke 1991; 22: 44-50.
24. Winquist RJ, Kerr S. Cerebral ischemia-reperfusion injury and adhesion. Neurology 1997; 49 (Suppl 4): S23-6.
25. Huang J, Kim LJ, Mealey R, Marsh HCJ, Zhang Y, Tenner AJ et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999; 285: 595-9.
26. Kato H, Kogure K, Liu X, Araki T, Itoyama Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res 1996; 734: 203-12.
27. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994; 25: 202-11.
28. Hallenbeck JM. Significance of the inflammatory response in brain ischemia. Acta Neurochirurgica - Supplementum 1996; 66: 27-31.
29. Zhang RL, Chopp M, Zaloga C, Zhang ZG, Jiang N, Gautam SC et al. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res 1995; 682: 182-8.
30. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation Research 1996; 94: 939-45.
31. Kuroda S, Siesjo BK. Reperfusion damage following focal cerebral ischemia: Pathophysiology and therapeutic windows. Clinical Neuroscience 1997; 4: 199-212.
32. Nishino H, Czurko A, Fukuda A, Hashitani T, Hida H, Karadi Z et al. Pathophysiological process after transient ischemia of the middle cerebral artery in the rat. Brain Res Bull 1994; 35: 51-6.
33. Bednar MM, Gross CE, Howard DB, Lynn M. Neutrophil activation in acute human central nervous system injury. Neurologicl Reasearch 1997; 19: 588-92.
34. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Molecular and Chemical Neuropathology 1994; 23: 103-14.
35. Kostulas N, Pelidou SH, Kivisakk P, Kostulas V, Link H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999; 30: 2174-9.
36. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992; 29: 243-6.
37. Casale TB, Carolan EJ. Combination of IL-8 plus TNF alpha induces additive neutrophil migration. Allergy & Asthma Proceedings 1999; 20: 361-3.
38. Iadecola C, Xu X, Zhang F, el-Fakahany E, Ross M. Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism 1995; 15: 52-9.
39. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. [Review]. Trends in Neurosciences 1997; 20: 132-9.
40. Grandati MPM, Verrecchia C, Revaud M, Allix M, Boulu R. Calcium-independent NO-synthase activity and nitrites/nitrates production in transient focal cerebral ischaemia in mice. British Journal of Pharmacology 1997; 122: 625-30.
41. Iadecola C, Zhang F, Casey R, Clark H, Ross M. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996; 27: 1373-80.
42. Iadecola C, Zhang F, Xu S, Casey R, Ross M. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism 1995; 15: 378-84.
43. Miettinen S, Fusco FR, Yrjanheikki J, Keinanen R, Hirvonen T, Roivainen R et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 6500-5.
44. Nogawa S, Forster C, Zhang F, Nagayama M, Ross M, Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 10966-71.
45. Nogawa S, Zhang F, Ross M, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. Journal of Neuroscience 1997; 17: 2746-55.
46. Planas A, Soriano M, Justicia C, Rodriguez-Farre E. Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neuroscience Letters 1999; 275: 141-4.
47. Nakayama M, Uchimura K, Zhu R, Nagayama T, Rose M, Stetler R et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 10954-9.
48. Iadecola C, Forster C, Nogawa S, Clark H, Ross M. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathologica 1999; 98: 9-14.
49. Billups KL, Palladino MA, Hinton BT, Sherley JL. Expression of E-selectin mRNA during ischemia/reperfusion injury. J Lab Clin Med 1995; 125: 626-33.
50. Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. British Medical Journal Clinical Research Ed. 1986; 292: 21-3.
51. de Courten-Myers GM, Kleinholz M, Wagner KR, Xi G, Myers RE. Efficacious experimental stroke treatment with high-dose methylprednisolone.[see comment]. Stroke. 1994; 25: 487-92; discussion 493.
52. de la Torre JC, Surgeon JW. Dexamethasone and DMSO in experimental transorbital cerebral infarction. Stroke. 1976; 7: 577-83.
53. Donley RF, Sundt TM Jr. The effect of dexamethasone on the edema of focal cerebral ischemia. Stroke 1973; 4: 148-55.
54. Harrison MJ, Brownbill D, Lewis PD, Russell RW. Cerebral edema following carotid artery ligation in the gerbil. Archives of Neurology 1973; 28: 389-91.
55. Hoppe WE, Waltz AG, Jordan MM, Jacobson RL. Effects of dexamethasone on distributions of water and pertechnetate in brains of cats after middle cerebral artery occlusion. Stroke. 1974; 5: 617-22.
56. Kahn K. The natural course of experimental cerebral infarction in the gerbil. Neurology 1972; 22: 510-5.
57. Lee MC, Mastri AR, Waltz AG, Loewenson RB. Ineffectiveness of dexamethasone for treatment of experimental cerebral infarction. Stroke 1974; 5: 216-8.
58. Little JR. Modification of acute focal ischemia by treatment with mannitol. Stroke 1978; 9: 4-9.
59. McGraw CP, Fleming DF Jr, Spruil JH. Effect of methylprednisolone on experimental cerebral infarction in the Mongolian gerbil. Stroke 1974; 5: 444-6.
60. Betz AL, Coester HC. Effect of steroid therapy on ischaemic brain oedema and blood to brain sodium transport. Acta Neurochirurgica - Supplementum 1990; 51: 256-8.
61. Bremer AM, Yamada K, West CR. Ischemic cerebral edema in primates: effects of acetazolamide, phenytoin, sorbitol, dexamethasone, and methylprednisolone on brain water and electrolytes. Neurosurgery 1980; 6: 149-54.
62. Harrison MJ, Russell RW. Effect of dexamethasone on experimental cerebral infarction in the gerbil. Journal of Neurology, Neurosurgery & Psychiatry 1972; 35: 520-1.
63. Iannotti F, Crockard A, Ladds G, Symon L. Are prostaglandins involved in experimental ischemic edema in gerbils? Stroke 1981; 12: 301-6.
64. Jarrott DM, Domer FR. A gerbil model of cerebral ischemia suitable for drug evaluation. Stroke 1980; 11: 203-9.
65. Laha RK, Dujovny M, Barrionuevo PJ, DeCastro SC, Hellstrom HR, Maroon JC. Protective effects of methyl prednisolone and dimethyl sulfoxide in experimental middle cerebral artery embolectomy. Journal of Neurosurgery 1978; 49: 508-16.
66. de Courten-Myers G, Myers RE, Schoolfield L. Hyperglycemia enlarges infarct size in cerebrovascular occlusion in cats. Stroke 1988; 19: 623-30.
67. de Courten-Myers GM, Myers RE, Wagner KR. Effect of hyperglycemia on infarct size after cerebrovascular occlusion in cats, [comment]. Stroke 1990; 21: 357-8.
68. de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE. Fatal strokes in hyperglycemic cats. Stroke 1989; 20: 1707-15.
69. Woo E, Ma JT, Robinson JD, Yu YL. Hyperglycemia is a stress response in acute stroke. Stroke 1988; 19: 1359-64.
70. Riddle MC, Hart J. Hyperglycemia, recognized and unrecognized, as a risk factor for stroke and transient ischemic attacks. Stroke 1982; 13: 356-9.
71. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993; 24: 111-6.
72. van Kooten F, Hoogerbrugge N, Naarding P, Koudstaal PJ. Hyperglycemia in the acute phase of stroke is not caused by stress. [see comment]. Stroke 1993; 24: 1129-32.
73. Tracey F, Stout RW. Hyperglycemia in the acute phase of stroke and stress response. [comment]. Stroke 1994; 25: 524-5.
74. Risau W, Hallman R, Albrecht U, Henke-Fahle S. Brain astrocytes induce the expression of an early cell surface marker for blood-brain barrier specific endothelium. EMBO Journal 1986; 5: 3179-83.
75. Thomas WS, Mori E, Copeland BR, Yu JQ, Morrisey JH, del Zoppo GJ. Tissue factor contributes to microvascular defects following cerebral ischemia. Stroke 1993; 24: 847-53.
76. Ames A, Wright RL, Kowada M, Thurston JM, Majno G. Cerebral ischemia: The no-reflow phenomenon. Am J Pathol 1968; 52: 437-53.
77. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-79.
78. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T et al. Role of cell adhesion molecules in brain injury after middle cerebral artery occlusion in the rat. Brain Res 1994; 656: 344-52.
79. Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. Experimental antileukocyte interventions in cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 1996; 16: 1108-19.
80. del Zoppo GJ. Microvascular responses to cerebral ischemia/inflammation. Annals of the New York Academy of Sciences 1997; 823: 132-47.
81. Bednar MM, Gross CE, Balazy M, Falck JR. Antineutrophil strategies. Neurology 1997; 49: S20-2.
82. Ahmed SH, He YY, Nassief A, Xu J, Xu XM, Hsu CY et al. Effects of lipopolysaccharide priming on acute ischemic brain injury. [comment]. Stroke 2000; 31: 193-9.
83. Barone FC, Hillegass LM, Tzimas MN, Schmidt DB, Foley JJ, White RF et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Molecular & Chemical Neuropathology 1995; 24: 13-30.
84. Barone FC, Schmidt DB, Hillegass LM, Price WJ, White RF, Feuerstein GZ et al. Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia. Stroke 1992; 23: 1337-47; discussion 1347-8.
85. Clark RK, Lee EV, Fish CJ, White RF, Price WJ, Jonak ZL, et al. Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitative planimetric study. Brain Research Bulletin 1993; 31: 565-72.
86. Clark RK, Lee EV, White RF, Jonak ZL, Feuerstein GZ, Barone FC. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue. Brain Research Bulletin 1994; 35: 387-92.
87. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). American Journal of Pathology 1994; 144: 188-99.
88. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. American Journal of Pathology 1993; 142: 623-35.
89. Jander S, Kraemer M, Schroeter M, Witte OW, Stoll G. Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. Journal of Cerebral Blood Flow & Metabolism 1995; 15: 42-51.
90. Ritter LS, Orozco JA, Coull BM, McDonagh PF, Rosenblum WI. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. Stroke 2000; 31: 1153-61.
91. Schroeter M, Jander S, Witte OW, Stoll G. Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. Journal of Neuroimmunology 1994; 55: 195-203.
92. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T et al. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Research 1994; 656: 344-52.
93. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. [comment]. Stroke 1995; 26: 676-80; discussion 681.
94. Zhang RL, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. [erratum appears in J Neurol Sci 1994 Oct; 126(1): 96]. Journal of the Neurological Sciences 1994; 125: 3-10.
95. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke [editorial]. Journal of Neurology, Neurosurgery & Psychiatry 1998; 65(1): 1-9.
96. Soriano SG, Coxon A, Wang YF, Frosch MP, Lipton SA, Hickey PR et al. Mice Deficient in Mac-1 (CD111b/CD18) Are Less Susceptible to Cerebral Ischemia/Reperfusion Injury • Editorial Comment. Stroke 1999; 30: 134-9.
97. Prestigiacomo CJ, Kim SC, Connolly ES Jr, Liao H, Yan SF, Pinsky DJ. CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999; 30: 1110-7.
98. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995; 45: 815-9.
99. Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR et al. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Annals of Neurology 1994; 35: 458-63.
100. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 1994; 25: 869-75; discussion 875-6.
101. Chopp M, Li Y, Jiang N, Zhang RL, Prostak J. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. Journal of Cerebral Blood Flow & Metabolism 1996; 16: 578-84.
102. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 1991; 22: 877-83.
103. Garcia JH, Liu KF, Bree MP. Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion. American Journal of Pathology 1996; 148: 241-8.
104. Zhang RL, Zhang ZG, Chopp M. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology 1999; 52: 273-9.
105. Bednar MM, Wright SD, Raymond-Russell SJ, Kohut JJ, Gross CE. IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Neurological Research. 1996; 18: 171-5.
106. Jiang N, Moyle M, Soule HR, Rote WE, Chopp M. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Annals of Neurology. 1995; 38: 935-42.
107. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Research 1998; 788: 25-34.
108. Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M, Chopp M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003; 34: 1790-5.
109. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29: 2129-35.
110. Kitagawa K, Matsumoto M, Mabuchi T, Yagita Y, Ohtsuki T, Hori M et al. Deficiency of intercellular adhesion molecule 1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism 1998; 18: 1336-45.
111. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
112. Connolly ES Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. Journal of Clinical Investigation 1996; 97: 209-16.
113. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Experimental Neurology 1993; 119: 215-9.
114. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C. The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Research 1998; 785: 207-14.
115. Connolly ES Jr, Winfree CJ, Prestigiacomo CJ, Kim SC, Choudhri TF, Hoh BL et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circulation Research 1997; 81: 304-10.
116. Goussev AV, Zhang Z, Anderson DC, Chopp M. P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. Journal of the Neurological Sciences 1998; 161: 16-22.
117. Huang J, Choudhri TF, Winfree CJ, McTaggart RA, Kiss S, Mocco J et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 2000; 31: 3047-53.
118. Zhang RL, Chopp M, Zhang ZG, Phillips ML, Rosenbloom CL, Cruz R et al. E-selectin in focal cerebral ischemia and reperfusion in the rat. Journal of Cerebral Blood Flow & Metabolism 1996; 16: 1126-36.
119. Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circulation Research 2002; 91: 907-14.
120. Huang J, Mocco J, Choudhri TF, Poisik A, Popilskis SJ, Emerson R et al. A modified transorbital baboon model of reperfused stroke. Stroke 2000; 31: 3054-63.
121. Enlimomab Acute Stroke Trial I. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001; 57: 1428-34.
122. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7.
123. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? International Disability Studies 1988; 10: 64-7.
124. Powers DW Assessment of the stroke patient using the NIH stroke scale. Emergency Medical Services 2001; 30: 52-6.
125. Vuorte J, Lindsberg PJ, Kaste M, Meri S, Jansson SE, Rothlein R et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. Journal of Immunology 1999; 162: 2353-7.
126. Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke 2001; 32: 2665-74.
127. Bowen JD, Petersdorf SH, Richards TL, Maravilla KR, Dale DC, Price TH et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clinical Pharmacology & Therapeutics 1998; 64: 339-46.
128. Rusnak JM, Kopecky SL, Clements IP, Gibbons RJ, Holland AE, Peterman HS et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). [comment]. American Journal of Cardiology 2001; 88: 482-7.
129. Yenari MA, Kunis D, Sun GH, Onley D, Watson L, Turner S et al. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Experimental Neurology 1998; 153: 223-33.
130. Becker KJ. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Current Medical Research & Opinion 2002; 18 Suppl 2: s18-22.
131. Seachrist L. ICOS ends Leukarrest program, plans to move pafase forward. In Bioworld Online. 2000.
132. Krams M LK, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN). An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke. Stroke 2003; 34: 2543-8.
133. Sughrue ME, Connolly ES Jr, Krams M, Lees KR, Hacke W, Grieve AP et al. Effectively Bridging the Preclinical/Clinical Gap: The Results of the ASTIN Trial * Response. Stroke 2004; 35: e81-82.
134. Anonymous. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.[comment]. New England Journal of Medicine 1995; 333: 1581-7.
135. Teasdale G, Jennett B. Assessment of coma and impaired conshy; sciousness. A practical scale. Lancet 1974; 2: 81-4.
136. Fisher M, Schaebitz W. An overview of acute stroke therapy: past, present, and future. Archives of Internal Medicine 2000; 160: 3196-206.
137. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. [comment]. JAMA 1999; 282: 2003-11.
138. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke 1999; 30: 2230-7.
139. Del Zoppo GJ, Von Kummer R, Hamman GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998; 65: 1-9.
140. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Advances in Experimental Medicine & Biology. 2002; 513: 87-113.
141. Mabuchi T, Kitagawa K, Ohtsuki T, Kuwabara K, Yagita Y, Yanagihara T et al. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 2000; 31: 1735-43.
142. Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 2002; 22: 308-17.
143. Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NE et al. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 2003; 23: 748-55.
144. Relton JK, Sloan KE, Frew EM, Whalley ET, Adams SP, Lobb RR. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke 2001; 32: 199-205.
145. Weaver M, Leshley K, Sands H, Gritman KR, Legos JJ, Tuma RF. LEX032, A Novel Recombinant Serpin, Protects the Brain after Transient Focal Ischemia. Microvascular Research 2002; 63: 327-34.
146. Yano T, Anraku S, Nakayama R, Ushijima K. Neuroprotective effect of urinary trypsin inhibitor against focal cerebral ischemia-reperfusion injury in rats. Anesthesiology 2003; 98: 465-73.
147. Shimakura A, Kanianaka Y, Ikeda Y, Kondo K, Suzuki Y, Umemura K. Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion. Brain Research. 2000; 858: 55-60.
148. Ren Y, Savill J. Apoptosis: the importance of being eaten. Cell Death & Differentiation 1998; 5: 563-8.
149. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. Journal of Experimental Medicine 2000; 192: 359-66.